AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis
AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis
Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.2,3
Voydeya（danicopan 片劑）已獲加拿大批准作爲拉伏利珠單抗或依庫珠單抗的附加劑，用於治療因血管外溶血（EVH）導致殘留溶血性貧血的陣發性夜間血紅蛋白尿症（PNH）成年患者。1 Voydeya是首款口服因子D抑制劑在標準護理的 Ultomiris（ravulizumab）或 Soliris（eculizumab）的基礎上添加藥物，以滿足大約 10-20% 的 PNH 患者在使用 C5 治療期間經歷臨床顯著血管外溶血 (EVH) 的需求抑制劑.2,3